Cargando…
Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
JSLRT
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628823/ https://www.ncbi.nlm.nih.gov/pubmed/37518271 http://dx.doi.org/10.3960/jslrt.23017 |
| _version_ | 1785131843630137344 |
|---|---|
| author | Saburi, Masuho Sakata, Masanori Kodama, Yousuke Uraisami, Keiichi Takata, Hiroyuki Miyazaki, Yasuhiko Wada, Junpei Urabe, Shogo Ohtsuka, Eiichi |
| author_facet | Saburi, Masuho Sakata, Masanori Kodama, Yousuke Uraisami, Keiichi Takata, Hiroyuki Miyazaki, Yasuhiko Wada, Junpei Urabe, Shogo Ohtsuka, Eiichi |
| author_sort | Saburi, Masuho |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10628823 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | JSLRT |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106288232023-11-08 Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab Saburi, Masuho Sakata, Masanori Kodama, Yousuke Uraisami, Keiichi Takata, Hiroyuki Miyazaki, Yasuhiko Wada, Junpei Urabe, Shogo Ohtsuka, Eiichi J Clin Exp Hematop Short Communication JSLRT 2023-07-28 /pmc/articles/PMC10628823/ /pubmed/37518271 http://dx.doi.org/10.3960/jslrt.23017 Text en © by The Japanese Society for Lymphoreticular Tissue Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License. |
| spellingShingle | Short Communication Saburi, Masuho Sakata, Masanori Kodama, Yousuke Uraisami, Keiichi Takata, Hiroyuki Miyazaki, Yasuhiko Wada, Junpei Urabe, Shogo Ohtsuka, Eiichi Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab |
| title | Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab |
| title_full | Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab |
| title_fullStr | Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab |
| title_full_unstemmed | Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab |
| title_short | Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab |
| title_sort | poor clinical outcome of relapsed/refractory diffuse large b-cell lymphoma with myc translocation treated with polatuzumab vedotin, bendamustine, and rituximab |
| topic | Short Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628823/ https://www.ncbi.nlm.nih.gov/pubmed/37518271 http://dx.doi.org/10.3960/jslrt.23017 |
| work_keys_str_mv | AT saburimasuho poorclinicaloutcomeofrelapsedrefractorydiffuselargebcelllymphomawithmyctranslocationtreatedwithpolatuzumabvedotinbendamustineandrituximab AT sakatamasanori poorclinicaloutcomeofrelapsedrefractorydiffuselargebcelllymphomawithmyctranslocationtreatedwithpolatuzumabvedotinbendamustineandrituximab AT kodamayousuke poorclinicaloutcomeofrelapsedrefractorydiffuselargebcelllymphomawithmyctranslocationtreatedwithpolatuzumabvedotinbendamustineandrituximab AT uraisamikeiichi poorclinicaloutcomeofrelapsedrefractorydiffuselargebcelllymphomawithmyctranslocationtreatedwithpolatuzumabvedotinbendamustineandrituximab AT takatahiroyuki poorclinicaloutcomeofrelapsedrefractorydiffuselargebcelllymphomawithmyctranslocationtreatedwithpolatuzumabvedotinbendamustineandrituximab AT miyazakiyasuhiko poorclinicaloutcomeofrelapsedrefractorydiffuselargebcelllymphomawithmyctranslocationtreatedwithpolatuzumabvedotinbendamustineandrituximab AT wadajunpei poorclinicaloutcomeofrelapsedrefractorydiffuselargebcelllymphomawithmyctranslocationtreatedwithpolatuzumabvedotinbendamustineandrituximab AT urabeshogo poorclinicaloutcomeofrelapsedrefractorydiffuselargebcelllymphomawithmyctranslocationtreatedwithpolatuzumabvedotinbendamustineandrituximab AT ohtsukaeiichi poorclinicaloutcomeofrelapsedrefractorydiffuselargebcelllymphomawithmyctranslocationtreatedwithpolatuzumabvedotinbendamustineandrituximab |